Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy.
Wesley Brandao, Nimansha Jain, Zhuoran Yin...
https://pubmed.ncbi.nlm.nih.gov/39813317/Actively Recruiting
Led by General Biophysics LLC · Updated on 2025-04-25
16
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the safety of inhaling xenon gas in healthy volunteers to support its future use as a treatment for neurodegenerative diseases like Alzheimers disease. This phase 1, open-label study aims to see if xenon gas can be safely inhaled without causing serious side effects. The study involves healthy adults aged 55 to 75 and is conducted at a single center. Participants receive xenon gas mixed with oxygen through an anesthesia face mask for one of four durations 10, 20, 30, or 45 minutes. Before the xenon inhalation, they are given Zofran to help prevent side effects. The gas flow and concentration are carefully controlled and monitored by an anesthesiologist during treatment. After inhalation, pure oxygen is given for five minutes, followed by at least two hours of monitoring before discharge. The study includes five visits over about two weeks a screening visit with physical exams, blood, urine, and ECG tests to confirm eligibility a treatment visit for xenon gas inhalation and three follow-up visits on days 1, 3, and 7 after treatment. At each visit, researchers will monitor vital signs, collect blood samples, and perform physical exams to assess safety and any treatment-related effects. After completing the study, participants return to their usual medical care providers.
CONDITIONS
Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
General Biophysics LLC
Lead Sponsor
National Institute on Aging (NIA)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Xenon Gas Inhalation | Observation Only |
|---|---|---|
| What it is | Participants inhale xenon gas mixed with oxygen for 10, 20, 30, or 45 minutes to evaluate safety and biological effects. | No inhalation of xenon gas or other experimental agent; participants are observed without intervention. |
| Role in study | Investigational intervention being studied for safety, tolerability, and effects on blood biomarkers. | Routine observation with no experimental intervention, as is standard in healthy older adults. |
| Primary use | Being evaluated for its safety profile and its effects on markers related to inflammation and potential neuroprotection. | Observation only; no active intervention. Monitors natural health status typical for this age group. |
| How it is given or performed | Xenon, mixed with oxygen, is inhaled through a mask or breathing system for a single session of 10, 20, 30, or 45 minutes. | No procedure performed; participants do not undergo experimental gas inhalation. |
| Evidence status | Human trial evidence is limited to early-phase studies focused on safety and biological markers; no outcomes in patients with disease are established. | Observation only is established practice and does not involve experimental evidence in this setting. |
| Important limitations | Results in healthy volunteers may not reflect safety or effects in patients with disease, or in other age groups. No data on long-term outcomes or repeated dosing. | Observation does not provide safety or efficacy data for any intervention, nor does it alter the biological state. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 7 days
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - 1 day
Participants receive xenon gas inhalation for 10, 20, 30, or 45 minutes under medical supervision, including monitoring of vital signs during and after administration.
1 treatment visit (in-person) with at least 2 hours of post-treatment monitoring
Duration - 7 days after treatment
Participants return for safety monitoring including blood tests, vital signs, physical exams, and ECG at 1, 3, and 7 days after treatment to assess health and treatment effects.
3 follow-up visits (in-person) on Days 1, 3, and 7 post-treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Wesley Brandao, Nimansha Jain, Zhuoran Yin...
https://pubmed.ncbi.nlm.nih.gov/39813317/General Biophysics LLC
Lead Sponsor
National Institute on Aging (NIA)
Collaborating Sponsor